Autolus Therapeutics plc (6A3A) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Autolus Therapeutics plc (6A3A) has a cash flow conversion efficiency ratio of -0.256x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-67.90 Million ≈ $-79.38 Million USD) by net assets (€265.45 Million ≈ $310.34 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Autolus Therapeutics plc - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how Autolus Therapeutics plc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Autolus Therapeutics plc debt and liabilities for a breakdown of total debt and financial obligations.
Autolus Therapeutics plc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Autolus Therapeutics plc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Regulus Resources Inc
V:REG
|
-0.015x |
|
SF Urban Properties AG
SW:SFPN
|
0.007x |
|
Lingsen Precision Industries Ltd
TW:2369
|
-0.006x |
|
Compass Therapeutics Inc.
NASDAQ:CMPX
|
-0.052x |
|
INPAQ Technology Co Ltd
TWO:6284
|
0.045x |
|
CMC Magnetics Corp
TW:2323
|
-0.033x |
|
Lands’ End Inc
NASDAQ:LE
|
-0.068x |
|
Semler Scientific Inc
NASDAQ:SMLR
|
-0.072x |
Annual Cash Flow Conversion Efficiency for Autolus Therapeutics plc (2017–2024)
The table below shows the annual cash flow conversion efficiency of Autolus Therapeutics plc from 2017 to 2024. For the full company profile with market capitalisation and key ratios, see 6A3A company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €427.32 Million ≈ $499.59 Million |
€-206.27 Million ≈ $-241.15 Million |
-0.483x | +63.04% |
| 2023-12-31 | €111.47 Million ≈ $130.32 Million |
€-145.59 Million ≈ $-170.21 Million |
-1.306x | -247.32% |
| 2022-12-31 | €298.67 Million ≈ $349.18 Million |
€-112.31 Million ≈ $-131.30 Million |
-0.376x | +0.04% |
| 2021-12-31 | €313.32 Million ≈ $366.30 Million |
€-117.86 Million ≈ $-137.79 Million |
-0.376x | +32.91% |
| 2020-12-31 | €210.03 Million ≈ $245.55 Million |
€-117.76 Million ≈ $-137.67 Million |
-0.561x | -40.79% |
| 2019-12-31 | €254.84 Million ≈ $297.93 Million |
€-101.48 Million ≈ $-118.65 Million |
-0.398x | -139.23% |
| 2018-12-31 | €255.47 Million ≈ $298.67 Million |
€-42.52 Million ≈ $-49.72 Million |
-0.166x | -45.09% |
| 2017-12-31 | €142.60 Million ≈ $166.72 Million |
€-16.36 Million ≈ $-19.13 Million |
-0.115x | -- |
About Autolus Therapeutics plc
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; A… Read more